Gaustadbekkdalen, photo: Ola Sæter
The Oslo based technology transfer offices Medinnova and Birkeland Innovasjon have merged. The new company is named Inven2. Jostein Dalland has been appointed CEO of Inven2. As of January 1, 2011, the company will be co-located at Oslo Innovation Center in one of the most concentrated physical campuses for bio-medical activity in the Nordic countries, Gaustadbekkdalen.
The Oslo University Hospital is the largest in Scandinavia forming a health trust that operates three university hospitals; Rikshospitalet including the Norwegian
Radium Hospital, Ullevål and Aker. The merger of Birkeland Innovation and Medinnova has resulted in the largest Technology Transfer Office (TTO) in Norway and the country’s leading actor commercializing life science opportunities.
By serving Oslo University and Oslo University Hospital, the new TTO represents about 80% of all Life Science research activity in Norway and has a particular emphasis on opportunities in the fields of cancer, neurosciences, and immunology.The company has a steady stream of new life science inventions with close to 200 invention disclosures annually and has since 2006 established 17 start-up companies in the Life Sciences and established more than 30 partnership of longer term cooperation between academics and national and international companies.
Strong concentration
Gaustadbekkdalen in Oslo contains one of the most concentrated physical campuses for bio-medical activity in the Nordic countries. The anchor at Gaustadbekkdalen is the close co-operation between Rikshospitalet (now Oslo University Hospital) Norway’s largest and most specialised hospital, and the neighbouring University of Oslo. The University is now planning a new cross-disciplinary research building within the life sciences. The Centre, if realised, will become one of the largest research and education investments in Norway this decade.
In connection to Gaustadbekkdalen, Montebello is home to the world famous Norwegian Radium Hospital (now Oslo University Hospital) which has
spun out a multitude of cancer-related companies. This is also the site of the new Oslo Cancer Cluster Innovation Park, which will physically combine the Radium Hospital with a new incubator for cancer biotechs and a high school campus to create a unique infrastructure for translational oncology.